Sinclair IS returns Episil rights to Camurus, retaining some distribution
UK-based specialty drugmaker Sinclair IS Pharma (AIM: SPH.L) has returned the commercial rights for Episil( benzydamine hydrochloride), a patented oral spray indicated for local treatment of pain associated with oral mucositis, in the European Union to Sweden’s Camurus AB, while retaining distribution rights in the UK and Ireland.
In conjunction with this, the group has assigned its rights under the distribution agreement with Israel’s Teva Pharmaceutical Industries (Nasdaq: TEVA) signed last year (The Pharma Letter September 1, 2012) to Camurus.
Sinclair IS says Episil remains core to its oncology supportive care franchise in the UK and Ireland, where the company continues to actively promote the product through its UK hospital sales force and its Irish partner, Fannin.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze